share_log

424B5: Prospectus

424B5: Prospectus

424B5：募資說明書
美股SEC公告 ·  05/08 07:48
Moomoo AI 已提取核心訊息
Clene Inc. has updated its prospectus supplement on May 8, 2024, to adjust the maximum aggregate gross sales price of its common stock offering to $12,300,000. This amendment is filed with the SEC and modifies the previous prospectus supplement dated November 7, 2023, and the accompanying prospectus dated April 26, 2022. The sales of the common stock will be conducted through Canaccord Genuity LLC, acting as the sales agent, on an 'at the market offering' basis as defined by Rule 415(a)(4). Canaccord Genuity is entitled to a commission of up to 3.0% per share sold and will also receive indemnification against certain liabilities. Clene's common stock and public warrants are traded on the Nasdaq under the symbols 'CLNN' and 'CLNNW,' with the last reported sale prices on...Show More
Clene Inc. has updated its prospectus supplement on May 8, 2024, to adjust the maximum aggregate gross sales price of its common stock offering to $12,300,000. This amendment is filed with the SEC and modifies the previous prospectus supplement dated November 7, 2023, and the accompanying prospectus dated April 26, 2022. The sales of the common stock will be conducted through Canaccord Genuity LLC, acting as the sales agent, on an 'at the market offering' basis as defined by Rule 415(a)(4). Canaccord Genuity is entitled to a commission of up to 3.0% per share sold and will also receive indemnification against certain liabilities. Clene's common stock and public warrants are traded on the Nasdaq under the symbols 'CLNN' and 'CLNNW,' with the last reported sale prices on May 6, 2024, being $0.4236 and $0.0393, respectively. The company's public float was valued at approximately $37.0 million as of the date of the supplement. Clene Inc. has not sold any shares under the General Instruction I.B.6 of Form S-3 in the 12 months preceding the date of the new prospectus supplement. The company warns that investing in its securities carries a high degree of risk.
Clene Inc.已於2024年5月8日更新了其招股說明書補充文件，將其普通股發行的最高總銷售價格調整爲12,300,000美元。該修正案已向美國證券交易委員會提交，修改了先前於2023年11月7日發佈的招股說明書補充文件以及隨附的2022年4月26日的招股說明書。普通股的銷售將通過作爲銷售代理的Canaccord Genuity LLC在規則415（a）（4）定義的 “市場發行” 基礎上進行。Canaccord Genuity有權獲得每股最高3.0％的佣金，還將獲得某些負債的賠償。克倫的普通股和公開認股權證在納斯達克上市，股票代碼爲 “CLNN” 和 “CLNNW”，上次公佈的銷售價格爲2...展開全部
Clene Inc.已於2024年5月8日更新了其招股說明書補充文件，將其普通股發行的最高總銷售價格調整爲12,300,000美元。該修正案已向美國證券交易委員會提交，修改了先前於2023年11月7日發佈的招股說明書補充文件以及隨附的2022年4月26日的招股說明書。普通股的銷售將通過作爲銷售代理的Canaccord Genuity LLC在規則415（a）（4）定義的 “市場發行” 基礎上進行。Canaccord Genuity有權獲得每股最高3.0％的佣金，還將獲得某些負債的賠償。克倫的普通股和公開認股權證在納斯達克上市，股票代碼爲 “CLNN” 和 “CLNNW”，上次公佈的銷售價格爲2024年5月6日，分別爲0.4236美元和0.0393美元。截至補編之日，該公司的公衆持股量約爲3,700萬美元。在新招股說明書補充文件發佈之日之前的12個月中，Clene Inc.沒有根據S-3表格第I.B.6號一般指示出售任何股票。該公司警告說，投資其證券具有高度的風險。

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息